| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rhabdomyosarcoma | 39 | 2025 | 211 | 12.080 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 14 | 2024 | 52 | 4.900 |
Why?
|
| Neoplasm Recurrence, Local | 27 | 2025 | 1316 | 3.960 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 24 | 2024 | 1357 | 3.680 |
Why?
|
| Hepatoblastoma | 12 | 2019 | 184 | 3.600 |
Why?
|
| Soft Tissue Neoplasms | 12 | 2025 | 128 | 3.570 |
Why?
|
| Child | 112 | 2025 | 25911 | 2.540 |
Why?
|
| Sarcoma | 10 | 2025 | 209 | 2.480 |
Why?
|
| Prognosis | 45 | 2025 | 5084 | 2.390 |
Why?
|
| Child, Preschool | 67 | 2025 | 14895 | 2.250 |
Why?
|
| Bone Neoplasms | 7 | 2025 | 447 | 2.220 |
Why?
|
| Kidney Neoplasms | 9 | 2024 | 462 | 2.140 |
Why?
|
| Infant | 60 | 2025 | 13256 | 2.100 |
Why?
|
| Adolescent | 75 | 2025 | 20643 | 2.070 |
Why?
|
| Thyroid Neoplasms | 5 | 2025 | 262 | 2.020 |
Why?
|
| Neuroendocrine Tumors | 3 | 2024 | 56 | 1.630 |
Why?
|
| Combined Modality Therapy | 15 | 2025 | 1312 | 1.610 |
Why?
|
| Wilms Tumor | 6 | 2024 | 119 | 1.570 |
Why?
|
| Cyclophosphamide | 8 | 2024 | 426 | 1.570 |
Why?
|
| Liver Neoplasms | 12 | 2019 | 1416 | 1.570 |
Why?
|
| Neoplasms | 11 | 2024 | 3035 | 1.540 |
Why?
|
| Survival Rate | 24 | 2025 | 2212 | 1.530 |
Why?
|
| Nasopharyngeal Neoplasms | 3 | 2018 | 62 | 1.520 |
Why?
|
| Follow-Up Studies | 27 | 2025 | 5465 | 1.490 |
Why?
|
| Bone Density Conservation Agents | 3 | 2021 | 56 | 1.460 |
Why?
|
| Male | 87 | 2025 | 66171 | 1.440 |
Why?
|
| Humans | 139 | 2025 | 134145 | 1.430 |
Why?
|
| Denosumab | 2 | 2021 | 14 | 1.390 |
Why?
|
| Female | 90 | 2025 | 72004 | 1.360 |
Why?
|
| Rare Diseases | 2 | 2024 | 209 | 1.320 |
Why?
|
| Young Adult | 33 | 2025 | 9960 | 1.310 |
Why?
|
| Vincristine | 5 | 2024 | 196 | 1.280 |
Why?
|
| Lung Diseases | 4 | 2014 | 406 | 1.260 |
Why?
|
| Lung Neoplasms | 9 | 2025 | 1783 | 1.250 |
Why?
|
| Thyroidectomy | 3 | 2025 | 112 | 1.170 |
Why?
|
| Biomarkers, Tumor | 13 | 2025 | 1721 | 1.160 |
Why?
|
| Neoplasms, Muscle Tissue | 2 | 2021 | 10 | 1.140 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 127 | 1.130 |
Why?
|
| Extremities | 2 | 2025 | 87 | 1.060 |
Why?
|
| Histiocytosis, Langerhans-Cell | 3 | 2014 | 240 | 1.020 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 6 | 2023 | 40 | 1.020 |
Why?
|
| Oncogene Proteins, Fusion | 6 | 2021 | 236 | 0.990 |
Why?
|
| Medical Oncology | 5 | 2024 | 247 | 0.990 |
Why?
|
| Sarcoma, Synovial | 2 | 2024 | 22 | 0.950 |
Why?
|
| Thoracic Wall | 2 | 2023 | 40 | 0.940 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2015 | 135 | 0.930 |
Why?
|
| Retrospective Studies | 33 | 2025 | 17565 | 0.920 |
Why?
|
| Sirolimus | 3 | 2024 | 239 | 0.900 |
Why?
|
| Ovarian Neoplasms | 3 | 2018 | 469 | 0.890 |
Why?
|
| Antineoplastic Agents | 10 | 2021 | 1853 | 0.880 |
Why?
|
| Pulmonary Blastoma | 2 | 2015 | 11 | 0.870 |
Why?
|
| Bevacizumab | 3 | 2020 | 79 | 0.860 |
Why?
|
| Myofibroma | 2 | 2020 | 9 | 0.820 |
Why?
|
| Granuloma, Giant Cell | 2 | 2020 | 12 | 0.810 |
Why?
|
| Phenylurea Compounds | 3 | 2021 | 56 | 0.800 |
Why?
|
| Lung | 4 | 2015 | 1577 | 0.800 |
Why?
|
| Carcinoma, Papillary | 2 | 2020 | 96 | 0.790 |
Why?
|
| Doxorubicin | 7 | 2023 | 303 | 0.780 |
Why?
|
| Melanoma | 2 | 2021 | 969 | 0.780 |
Why?
|
| Quinolines | 3 | 2021 | 114 | 0.770 |
Why?
|
| Skin Neoplasms | 2 | 2020 | 907 | 0.750 |
Why?
|
| Biliary Tract | 1 | 2021 | 15 | 0.750 |
Why?
|
| Disease-Free Survival | 10 | 2023 | 972 | 0.740 |
Why?
|
| Neoadjuvant Therapy | 3 | 2023 | 406 | 0.740 |
Why?
|
| Bone Marrow | 1 | 2023 | 335 | 0.740 |
Why?
|
| Osteolysis, Essential | 2 | 2012 | 4 | 0.730 |
Why?
|
| Puberty, Precocious | 2 | 2019 | 29 | 0.720 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2021 | 7 | 0.710 |
Why?
|
| Melanosis | 1 | 2021 | 10 | 0.710 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2021 | 16 | 0.700 |
Why?
|
| Osteosarcoma | 3 | 2021 | 264 | 0.690 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2021 | 21 | 0.690 |
Why?
|
| Papilloma | 1 | 2020 | 22 | 0.690 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 2020 | 14 | 0.690 |
Why?
|
| Infant, Newborn | 19 | 2022 | 8636 | 0.680 |
Why?
|
| Myofibromatosis | 1 | 2020 | 10 | 0.680 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2020 | 18 | 0.660 |
Why?
|
| Ependymoma | 2 | 2013 | 176 | 0.660 |
Why?
|
| Cyclin B | 1 | 2019 | 23 | 0.650 |
Why?
|
| GTP Phosphohydrolases | 1 | 2021 | 158 | 0.650 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2019 | 21 | 0.650 |
Why?
|
| Aicardi Syndrome | 1 | 2019 | 15 | 0.640 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2022 | 625 | 0.640 |
Why?
|
| Agenesis of Corpus Callosum | 1 | 2019 | 44 | 0.640 |
Why?
|
| Registries | 5 | 2020 | 1586 | 0.630 |
Why?
|
| Chromosomes, Human, Pair 13 | 3 | 2015 | 51 | 0.620 |
Why?
|
| Head and Neck Neoplasms | 1 | 2025 | 701 | 0.610 |
Why?
|
| Leydig Cell Tumor | 1 | 2019 | 7 | 0.610 |
Why?
|
| Bronchial Neoplasms | 1 | 2019 | 15 | 0.610 |
Why?
|
| Carcinoma | 3 | 2021 | 321 | 0.610 |
Why?
|
| Orchiectomy | 1 | 2019 | 53 | 0.600 |
Why?
|
| Carcinoid Tumor | 1 | 2019 | 27 | 0.600 |
Why?
|
| Adult | 27 | 2025 | 31944 | 0.600 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2018 | 4 | 0.590 |
Why?
|
| Meningeal Neoplasms | 1 | 2021 | 217 | 0.590 |
Why?
|
| Repressor Proteins | 2 | 2022 | 874 | 0.580 |
Why?
|
| Salvage Therapy | 2 | 2024 | 202 | 0.580 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2018 | 556 | 0.570 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2018 | 11 | 0.570 |
Why?
|
| Treatment Outcome | 16 | 2024 | 13098 | 0.560 |
Why?
|
| Femoral Neoplasms | 2 | 2015 | 8 | 0.560 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2019 | 401 | 0.560 |
Why?
|
| Pancreatic Neoplasms | 1 | 2024 | 739 | 0.560 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 135 | 0.560 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 1344 | 0.550 |
Why?
|
| Granulosa Cell Tumor | 2 | 2018 | 39 | 0.550 |
Why?
|
| Respiratory Tract Infections | 1 | 2020 | 294 | 0.550 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 2 | 2016 | 115 | 0.540 |
Why?
|
| Neoplasm Staging | 8 | 2023 | 1391 | 0.540 |
Why?
|
| Bleomycin | 2 | 2014 | 153 | 0.530 |
Why?
|
| Translocation, Genetic | 2 | 2016 | 363 | 0.530 |
Why?
|
| Fertility Preservation | 1 | 2017 | 58 | 0.520 |
Why?
|
| Hepatectomy | 2 | 2014 | 124 | 0.520 |
Why?
|
| Oncogene Proteins | 2 | 2014 | 157 | 0.510 |
Why?
|
| Survivors | 4 | 2015 | 358 | 0.500 |
Why?
|
| Cough | 2 | 2014 | 97 | 0.500 |
Why?
|
| Deoxycytidine | 1 | 2016 | 84 | 0.490 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2015 | 3 | 0.490 |
Why?
|
| Brain Neoplasms | 3 | 2022 | 1406 | 0.490 |
Why?
|
| Dyspnea | 2 | 2014 | 160 | 0.490 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 399 | 0.490 |
Why?
|
| Hemangioendothelioma | 1 | 2015 | 25 | 0.480 |
Why?
|
| Nose Neoplasms | 1 | 2015 | 34 | 0.480 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2015 | 45 | 0.480 |
Why?
|
| Gene Fusion | 3 | 2022 | 61 | 0.470 |
Why?
|
| Nasal Cavity | 1 | 2015 | 52 | 0.470 |
Why?
|
| Clinical Trials as Topic | 6 | 2024 | 1161 | 0.460 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2015 | 150 | 0.460 |
Why?
|
| Myositis | 1 | 2016 | 105 | 0.460 |
Why?
|
| Chromosome Disorders | 2 | 2013 | 316 | 0.450 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2016 | 198 | 0.450 |
Why?
|
| Eczema | 1 | 2014 | 30 | 0.450 |
Why?
|
| Pituitary Gland | 1 | 2014 | 89 | 0.440 |
Why?
|
| Forkhead Box Protein O1 | 3 | 2025 | 99 | 0.440 |
Why?
|
| Beckwith-Wiedemann Syndrome | 1 | 2014 | 16 | 0.440 |
Why?
|
| Adamantinoma | 1 | 2014 | 2 | 0.440 |
Why?
|
| Whole-Body Irradiation | 1 | 2014 | 61 | 0.440 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2024 | 83 | 0.430 |
Why?
|
| Research Report | 1 | 2014 | 78 | 0.430 |
Why?
|
| Rhabdoid Tumor | 1 | 2014 | 56 | 0.430 |
Why?
|
| Carboplatin | 1 | 2014 | 87 | 0.420 |
Why?
|
| Abnormalities, Multiple | 1 | 2019 | 979 | 0.420 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2014 | 104 | 0.420 |
Why?
|
| Tibia | 1 | 2014 | 83 | 0.420 |
Why?
|
| Neoplasms, Second Primary | 3 | 2024 | 166 | 0.400 |
Why?
|
| Membrane Proteins | 1 | 2021 | 1621 | 0.400 |
Why?
|
| Remission Induction | 3 | 2019 | 310 | 0.390 |
Why?
|
| Bone and Bones | 1 | 2014 | 311 | 0.380 |
Why?
|
| Dactinomycin | 2 | 2024 | 66 | 0.380 |
Why?
|
| Splenic Diseases | 1 | 2012 | 31 | 0.380 |
Why?
|
| Nuclear Proteins | 3 | 2018 | 1351 | 0.360 |
Why?
|
| Necrosis | 1 | 2011 | 220 | 0.360 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 255 | 0.350 |
Why?
|
| Hodgkin Disease | 1 | 2014 | 298 | 0.350 |
Why?
|
| Pleural Effusion | 1 | 2012 | 109 | 0.350 |
Why?
|
| Radiotherapy Dosage | 4 | 2025 | 233 | 0.350 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2022 | 65 | 0.350 |
Why?
|
| Lymphangioma | 1 | 2010 | 25 | 0.350 |
Why?
|
| Congenital Abnormalities | 1 | 2014 | 298 | 0.340 |
Why?
|
| Supratentorial Neoplasms | 1 | 2011 | 40 | 0.340 |
Why?
|
| Databases, Factual | 2 | 2025 | 1258 | 0.340 |
Why?
|
| Disease Management | 3 | 2021 | 567 | 0.340 |
Why?
|
| Watchful Waiting | 1 | 2011 | 78 | 0.330 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 349 | 0.320 |
Why?
|
| Respiratory Function Tests | 3 | 2014 | 215 | 0.310 |
Why?
|
| Postoperative Care | 1 | 2011 | 309 | 0.300 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2015 | 2203 | 0.300 |
Why?
|
| Risk Factors | 8 | 2022 | 11184 | 0.300 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2021 | 168 | 0.300 |
Why?
|
| Ifosfamide | 3 | 2023 | 35 | 0.300 |
Why?
|
| Radionuclide Imaging | 2 | 2021 | 151 | 0.270 |
Why?
|
| Datasets as Topic | 2 | 2025 | 105 | 0.270 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 609 | 0.260 |
Why?
|
| Organoplatinum Compounds | 3 | 2014 | 34 | 0.240 |
Why?
|
| Chemoradiotherapy | 2 | 2017 | 127 | 0.240 |
Why?
|
| Cohort Studies | 5 | 2024 | 5219 | 0.230 |
Why?
|
| Risk Assessment | 3 | 2024 | 3752 | 0.230 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 407 | 0.230 |
Why?
|
| Perineum | 1 | 2024 | 48 | 0.220 |
Why?
|
| Neoplasm, Residual | 2 | 2025 | 134 | 0.220 |
Why?
|
| Anus Neoplasms | 1 | 2024 | 42 | 0.220 |
Why?
|
| Octreotide | 1 | 2024 | 25 | 0.220 |
Why?
|
| Prospective Studies | 6 | 2024 | 6610 | 0.220 |
Why?
|
| Margins of Excision | 1 | 2024 | 59 | 0.220 |
Why?
|
| Anthracyclines | 2 | 2014 | 44 | 0.220 |
Why?
|
| Incidence | 5 | 2022 | 3421 | 0.220 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 1982 | 0.210 |
Why?
|
| Iodine Radioisotopes | 2 | 2021 | 79 | 0.210 |
Why?
|
| Europe | 1 | 2024 | 382 | 0.210 |
Why?
|
| Radiopharmaceuticals | 2 | 2021 | 171 | 0.210 |
Why?
|
| Induction Chemotherapy | 2 | 2020 | 57 | 0.210 |
Why?
|
| Dacarbazine | 2 | 2013 | 99 | 0.200 |
Why?
|
| Camptothecin | 2 | 2013 | 79 | 0.200 |
Why?
|
| Maximum Tolerated Dose | 2 | 2013 | 174 | 0.200 |
Why?
|
| Cisplatin | 2 | 2015 | 287 | 0.200 |
Why?
|
| United States | 5 | 2025 | 11777 | 0.200 |
Why?
|
| Orbital Neoplasms | 1 | 2023 | 59 | 0.190 |
Why?
|
| Neuroblastoma | 2 | 2020 | 551 | 0.190 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 39 | 0.190 |
Why?
|
| Texas | 4 | 2019 | 3714 | 0.190 |
Why?
|
| Eyelids | 1 | 2023 | 104 | 0.190 |
Why?
|
| Clinical Decision-Making | 1 | 2024 | 298 | 0.190 |
Why?
|
| Lymphatic Metastasis | 3 | 2025 | 452 | 0.190 |
Why?
|
| Treatment Failure | 3 | 2025 | 365 | 0.190 |
Why?
|
| Methotrexate | 2 | 2015 | 355 | 0.190 |
Why?
|
| alpha-Fetoproteins | 2 | 2013 | 134 | 0.190 |
Why?
|
| Time-to-Treatment | 2 | 2020 | 204 | 0.190 |
Why?
|
| Intersectoral Collaboration | 1 | 2021 | 21 | 0.180 |
Why?
|
| Mammary Analogue Secretory Carcinoma | 1 | 2021 | 8 | 0.180 |
Why?
|
| Proportional Hazards Models | 5 | 2025 | 1486 | 0.180 |
Why?
|
| Pyrimidines | 2 | 2023 | 419 | 0.180 |
Why?
|
| Liposarcoma | 1 | 2021 | 25 | 0.180 |
Why?
|
| Radioisotopes | 1 | 2021 | 37 | 0.180 |
Why?
|
| Sulfones | 1 | 2021 | 75 | 0.180 |
Why?
|
| Tumor Burden | 2 | 2025 | 259 | 0.180 |
Why?
|
| Receptors, Peptide | 1 | 2021 | 54 | 0.180 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2021 | 67 | 0.180 |
Why?
|
| SEER Program | 2 | 2019 | 224 | 0.170 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2020 | 32 | 0.170 |
Why?
|
| Biopsy | 2 | 2015 | 1301 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2020 | 26 | 0.170 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 79 | 0.170 |
Why?
|
| Mutation | 4 | 2025 | 6341 | 0.160 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2020 | 96 | 0.160 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 136 | 0.160 |
Why?
|
| Global Burden of Disease | 1 | 2019 | 32 | 0.160 |
Why?
|
| DNA, Neoplasm | 1 | 2020 | 320 | 0.160 |
Why?
|
| Foot Diseases | 1 | 2019 | 23 | 0.160 |
Why?
|
| Thoracic Neoplasms | 1 | 2019 | 38 | 0.160 |
Why?
|
| Corpus Callosum | 1 | 2019 | 104 | 0.160 |
Why?
|
| Recurrence | 3 | 2023 | 1470 | 0.150 |
Why?
|
| Thigh | 1 | 2019 | 52 | 0.150 |
Why?
|
| Rectal Neoplasms | 1 | 2020 | 81 | 0.150 |
Why?
|
| Positron-Emission Tomography | 1 | 2021 | 312 | 0.150 |
Why?
|
| Liver Transplantation | 4 | 2019 | 1122 | 0.150 |
Why?
|
| Neutropenia | 1 | 2020 | 205 | 0.150 |
Why?
|
| Carcinoma, Small Cell | 1 | 2018 | 49 | 0.150 |
Why?
|
| Lymph Nodes | 1 | 2020 | 397 | 0.150 |
Why?
|
| Nephrectomy | 1 | 2019 | 181 | 0.150 |
Why?
|
| Etoposide | 2 | 2021 | 120 | 0.140 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2018 | 19 | 0.140 |
Why?
|
| Mentoring | 1 | 2019 | 82 | 0.140 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2019 | 211 | 0.140 |
Why?
|
| DiGeorge Syndrome | 1 | 2018 | 82 | 0.140 |
Why?
|
| Pediatrics | 2 | 2024 | 1221 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2024 | 1144 | 0.140 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 424 | 0.140 |
Why?
|
| Mentors | 1 | 2019 | 162 | 0.140 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2018 | 105 | 0.140 |
Why?
|
| Bacterial Infections | 1 | 2020 | 329 | 0.130 |
Why?
|
| Trisomy 13 Syndrome | 2 | 2013 | 19 | 0.130 |
Why?
|
| Infant, Premature, Diseases | 1 | 2019 | 254 | 0.130 |
Why?
|
| Appendiceal Neoplasms | 1 | 2017 | 20 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2019 | 251 | 0.130 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 1764 | 0.130 |
Why?
|
| Laparotomy | 1 | 2017 | 143 | 0.130 |
Why?
|
| Trisomy | 2 | 2013 | 112 | 0.130 |
Why?
|
| Hypertension, Malignant | 1 | 2016 | 6 | 0.130 |
Why?
|
| Bile Duct Neoplasms | 1 | 2018 | 121 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 2018 | 121 | 0.130 |
Why?
|
| Adrenocortical Adenoma | 1 | 2016 | 13 | 0.130 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2016 | 37 | 0.120 |
Why?
|
| Ovariectomy | 1 | 2016 | 189 | 0.120 |
Why?
|
| Renin | 1 | 2016 | 88 | 0.120 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2016 | 35 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2016 | 78 | 0.120 |
Why?
|
| Sacrum | 1 | 2015 | 31 | 0.120 |
Why?
|
| Melphalan | 1 | 2015 | 45 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2016 | 95 | 0.120 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2020 | 561 | 0.120 |
Why?
|
| Paraffin Embedding | 1 | 2015 | 41 | 0.120 |
Why?
|
| Diphosphonates | 1 | 2015 | 43 | 0.120 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 258 | 0.120 |
Why?
|
| Diabetes Insipidus | 1 | 2014 | 17 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 827 | 0.120 |
Why?
|
| Liver Diseases | 1 | 2019 | 392 | 0.110 |
Why?
|
| Hepatic Veins | 1 | 2014 | 24 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2015 | 148 | 0.110 |
Why?
|
| Utah | 1 | 2014 | 83 | 0.110 |
Why?
|
| Vascular Neoplasms | 1 | 2014 | 34 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2016 | 253 | 0.110 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2017 | 216 | 0.110 |
Why?
|
| Radiation Injuries | 1 | 2015 | 166 | 0.110 |
Why?
|
| Quality of Life | 1 | 2024 | 2162 | 0.110 |
Why?
|
| Vena Cava, Inferior | 1 | 2014 | 103 | 0.110 |
Why?
|
| Imidazoles | 1 | 2015 | 220 | 0.110 |
Why?
|
| Whole Body Imaging | 1 | 2014 | 31 | 0.110 |
Why?
|
| Carnitine | 1 | 2014 | 78 | 0.110 |
Why?
|
| Infant, Premature | 1 | 2019 | 857 | 0.110 |
Why?
|
| Stem Cell Transplantation | 1 | 2015 | 252 | 0.110 |
Why?
|
| Actins | 1 | 2016 | 353 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 510 | 0.100 |
Why?
|
| Disease Progression | 2 | 2025 | 2265 | 0.100 |
Why?
|
| Radiation Pneumonitis | 1 | 2013 | 12 | 0.100 |
Why?
|
| Demography | 1 | 2014 | 247 | 0.100 |
Why?
|
| Forced Expiratory Volume | 1 | 2014 | 173 | 0.100 |
Why?
|
| Leucovorin | 1 | 2013 | 54 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 546 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2019 | 1006 | 0.100 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2014 | 176 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2014 | 378 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 1070 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2017 | 560 | 0.100 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 719 | 0.100 |
Why?
|
| International Cooperation | 2 | 2025 | 169 | 0.100 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2013 | 93 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 1332 | 0.100 |
Why?
|
| Los Angeles | 1 | 2012 | 16 | 0.100 |
Why?
|
| Germ Cells | 2 | 2024 | 204 | 0.100 |
Why?
|
| Radiography | 1 | 2014 | 826 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 1070 | 0.090 |
Why?
|
| Transcription Factors | 3 | 2018 | 2734 | 0.090 |
Why?
|
| Laparoscopy | 1 | 2017 | 520 | 0.090 |
Why?
|
| Paired Box Transcription Factors | 2 | 2023 | 77 | 0.090 |
Why?
|
| Genomics | 1 | 2020 | 1678 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 1626 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1044 | 0.090 |
Why?
|
| Liver | 2 | 2019 | 1876 | 0.080 |
Why?
|
| Immunotherapy | 2 | 2014 | 750 | 0.080 |
Why?
|
| Cancer Survivors | 2 | 2024 | 251 | 0.080 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 565 | 0.080 |
Why?
|
| Pneumonia | 1 | 2013 | 343 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 1735 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2014 | 523 | 0.080 |
Why?
|
| Kidney Transplantation | 1 | 2015 | 574 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2025 | 745 | 0.080 |
Why?
|
| RNA, Messenger | 1 | 2015 | 2915 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2014 | 3677 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 2315 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 867 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 1922 | 0.070 |
Why?
|
| Genetic Therapy | 1 | 2012 | 738 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 3056 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2011 | 1595 | 0.070 |
Why?
|
| Age Factors | 1 | 2014 | 2997 | 0.070 |
Why?
|
| Prevalence | 1 | 2014 | 2683 | 0.070 |
Why?
|
| Inflammation | 1 | 2013 | 1595 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 1493 | 0.050 |
Why?
|
| Hematoxylin | 1 | 2023 | 8 | 0.050 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2023 | 9 | 0.050 |
Why?
|
| Mediator Complex | 1 | 2023 | 57 | 0.050 |
Why?
|
| Nucleotides | 1 | 2023 | 96 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2022 | 40 | 0.050 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2022 | 54 | 0.050 |
Why?
|
| DNA Mismatch Repair | 1 | 2022 | 54 | 0.050 |
Why?
|
| European Union | 1 | 2021 | 13 | 0.050 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2021 | 9 | 0.050 |
Why?
|
| Salivary Glands | 1 | 2021 | 35 | 0.050 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2022 | 76 | 0.050 |
Why?
|
| Drug Industry | 1 | 2021 | 48 | 0.050 |
Why?
|
| Precision Medicine | 1 | 2025 | 361 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 2091 | 0.040 |
Why?
|
| Reoperation | 1 | 2024 | 851 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2022 | 179 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 159 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 393 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2022 | 331 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 3867 | 0.040 |
Why?
|
| Radiation Dosage | 1 | 2020 | 147 | 0.040 |
Why?
|
| Endosonography | 1 | 2020 | 81 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 370 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2019 | 53 | 0.040 |
Why?
|
| Hypercalcemia | 1 | 2018 | 42 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 728 | 0.040 |
Why?
|
| Social Class | 1 | 2019 | 210 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 288 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 1251 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 2018 | 135 | 0.040 |
Why?
|
| Codon, Nonsense | 1 | 2018 | 144 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2020 | 249 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2019 | 457 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2018 | 253 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2024 | 1105 | 0.030 |
Why?
|
| Everolimus | 1 | 2016 | 51 | 0.030 |
Why?
|
| Colectomy | 1 | 2017 | 84 | 0.030 |
Why?
|
| Appendectomy | 1 | 2017 | 86 | 0.030 |
Why?
|
| Heterozygote | 1 | 2018 | 728 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2017 | 129 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 652 | 0.030 |
Why?
|
| Karyotyping | 1 | 2016 | 323 | 0.030 |
Why?
|
| Ovary | 1 | 2018 | 390 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 1880 | 0.030 |
Why?
|
| Appendicitis | 1 | 2017 | 130 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 192 | 0.030 |
Why?
|
| Global Health | 1 | 2019 | 623 | 0.030 |
Why?
|
| Exercise Test | 1 | 2015 | 263 | 0.030 |
Why?
|
| Middle Aged | 3 | 2025 | 29395 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 456 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 795 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2014 | 34 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 638 | 0.030 |
Why?
|
| Hyperammonemia | 1 | 2014 | 62 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2022 | 2177 | 0.030 |
Why?
|
| Ventricular Remodeling | 1 | 2014 | 191 | 0.030 |
Why?
|
| Muscular Diseases | 1 | 2014 | 116 | 0.030 |
Why?
|
| Epigenomics | 1 | 2014 | 196 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 827 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2014 | 363 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2014 | 382 | 0.020 |
Why?
|
| Animals | 1 | 2012 | 36520 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2023 | 3170 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 709 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 2014 | 519 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 2771 | 0.020 |
Why?
|
| Echocardiography | 1 | 2014 | 1132 | 0.020 |
Why?
|
| Aged | 1 | 2025 | 21789 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 2562 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 3758 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2014 | 2043 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 3800 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 4605 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3508 | 0.010 |
Why?
|
| Biomarkers | 1 | 2014 | 3431 | 0.010 |
Why?
|